CSTL — CASTLE BIOSCIENCES INC
—
Nasdaq ·
Health Care ·
Health Care Providers & Services ·
CIK 1447362 ·
Last close
$33.47
Market Cap
$1.02B
52W High
$34.70
52W Low
$19.51
ADV30
459,512
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 103,546,000 | 79,846,000 | -3,070,000 | -2,060,000 | 561,177,000 | 62,116,000 | 91,147,000 |
| Mar 2026 | 83,679,000 | 63,146,000 | -18,407,000 | -14,522,000 | 547,805,000 | 63,764,000 | 86,389,000 |
| Dec 2025 | 87,010,000 | 68,695,000 | -3,827,000 | -2,332,000 | 578,556,000 | 116,729,000 | 107,683,000 |
| Sep 2025 | 83,043,000 | 64,339,000 | -6,804,000 | -501,000 | 562,786,000 | 85,556,000 | 95,740,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$42,634,000
Investing CF
$-51,324,000
Financing CF
$-11,427,000
CapEx
$-43,123,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.66
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-240,866,000
Inventory
$10,580,000
Receivables
$48,341,000
ST Investments
$204,689,000
EBIT TTM
$-18,828,000
Pretax Income TTM
$-19,203,000
Interest Exp TTM
$375,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$357,278,016
EBITDA
$-16,516,000
Free Cash Flow
$-7,256,375
Enterprise Value
$792,337,024
Total Cash
$266,804,992
Total Debt
$36,650,000
Shares Out
30,549,507
Trailing EPS
$-0.64
Book Value
$15.41
ROE
-4.2%
ROA
-1.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 344,229,000 | -42,810,000 | -24,158,000 | 578,556,000 | 107,683,000 | — | 64,347,000 |
| Dec 2024 | 332,069,000 | 8,670,000 | 18,245,000 | 531,235,000 | 75,400,000 | — | 64,866,000 |
| Dec 2023 | 219,788,000 | -67,977,000 | -57,466,000 | 453,340,000 | 62,071,000 | — | -5,626,000 |
| Dec 2022 | 137,039,000 | -91,142,000 | -67,138,000 | 447,329,000 | 48,179,000 | — | -41,655,000 |
TTM Snapshot
Revenues TTM
$208,981,000
NetIncome TTM
$-30,025,000
OpCashFlow TTM
$0
Assets (Latest)
$531,235,000
Forward EPS
$-0.99
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $20.00 · spot: $33.47 · call volume: 214 · put volume: 29Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TDOC | Teladoc Health, Inc. | $1.13B | $6.20 | — |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.14B | $11.85 | — |
| USPH | U S PHYSICAL THERAPY INC /NV | $1.15B | $77.38 | — |
| TALK | Talkspace, Inc. | $870.58M | $5.25 | — |
| PNTG | Pennant Group, Inc. | $1.36B | $38.89 | — |
News headlines (Yahoo Finance, 1h cache)
Castle Biosciences to Participate in Upcoming Investor Conferences
2026-08-20 11:00 · Yahoo
Castle Biosciences Approved for Dual Listing on Nasdaq Texas
2026-08-17 11:00 · Yahoo
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction
2026-08-13 05:01 · Yahoo
Castle Biosciences, Inc. Q2 2026 Earnings Call Summary
2026-07-31 12:30 · Yahoo
Castle Biosciences Inc (CSTL) (Q2 2026) Earnings Call Highlights: Revenue Surges 20% to $103. ...
2026-07-31 05:03 · Yahoo
Castle Biosciences Q2 Earnings Call Highlights
2026-07-30 22:04 · Yahoo
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
2026-07-30 22:00 · Yahoo
Castle Biosciences Reports Second Quarter 2026 Results
2026-07-30 20:05 · Yahoo
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
2026-07-22 11:00 · Yahoo
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
2026-07-14 20:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.